Diagnosis and Management of Accelerated Phase CML

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: September 11, 2015
Expiration Date: September 11, 2016

Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Chronic myeloid leukemia (CML) is a small-population cancer; some 6,600 cases are anticipated to be diagnosed in the United States in 2015. The introduction of tyrosine kinase inhibitors (TKIs) in 1998 transformed the management of CML, and has led to significantly reduced mortality and improved 5-year survival rates. Nevertheless, the CML health care community is faced with several clinical challenges that need to be addressed. While the vast majority of CML patients are diagnosed with chronic phase (CP) CML, 10% to 15% of CML patients are diagnosed in advanced phase, primarily patients who have entered accelerated phase (AP), while small numbers of chronic phase (CP) cases experience disease progression each year during treatment. Early effective management of these patients is essential and requires additional considerations beyond those for CP-CML. Factors that play an important role in effectively managing these poor prognosis patients today include the appropriate diagnosis of AP-CML while recognizing available treatment options for these patients and selecting those that are most suited for the individual patient. It also must be kept in mind, for these patients, TKIs induce only transient responses and alternative treatment strategies are urgently required.

Join Managing CML experts B. Douglas Smith, MD, associate professor of oncology, Johns Hopkins University School of Medicine, and Jonathan A. Webster, MD, an oncology fellow at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, in a case-based presentation regarding the diagnosis and treatment planning of a CML patient who is in accelerated phase at the time of diagnosis. Topics covered include the criteria for diagnosis of AP-CML, review of treatment options and treatment selection, monitoring for response to treatment, and navigating subsequent progression with the emergence of a T315I mutation.

Target Audience

This activity is designed for hematologists, oncologists, and associated multidisciplinary clinical specialists who provide care to patients with CML.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Recall the criteria for accelerated phase chronic myeloid leukemia (CML)
  • Identify treatment goals and strategies for accelerated phase CML patient management
  • Recognize clinical barriers for the management of accelerated phase CML


Diagnosis and Management of Accelerated Phase CML − Jonathan Webster, MD, and B. Douglas Smith, MD

Instructions for Participation and Credit

This activity is eligible for credit through September 11, 2016. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Jonathan A. Webster, MD
Oncology Fellow
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Hospital
Baltimore, Maryland

Dr. Jonathan Webster received his medical degree from Stanford University School of Medicine, Stanford, California. He completed his internship and residency in internal medicine at The Johns Hopkins Hospital, Baltimore, Maryland where he is currently an oncology fellow. Dr. Webster has been published in several peer-reviewed publications including The Journal of Biological Chemistry, Journal of Clinical Oncology, The Journal of Pathology, Breast Cancer Research and Treatment, and Nature Chemical Biology.

B. Douglas Smith, MD
Associate Professor of Oncology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Dr. B. Douglas Smith received his medical degree from the Medical College of Pennsylvania in Philadelphia. He was a resident/chief resident in medicine at Strong Memorial Hospital in Rochester, New York, and an oncology fellow at the Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland. Dr. Smith is associate professor of oncology at Johns Hopkins University School of Medicine and on the active staff of Johns Hopkins Hospital.

A member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Association for Cancer Research, Dr. Smith developed the first tumor banking protocol in hematologic malignancies and now serves as the co-director of the cancer center’s specimen accessioning core. He also serves as co-investigator for the oncology center’s UM1 (phase I) grant. He is a recognized national leader in new therapeutics for AML and CML and currently serves on the NCCN guideline panels for both of these diseases. Dr. Smith also supports the SKCCC and Department of Oncology by serving as the co-chair of institutional review board-2.

Dr. Smith’s research focuses on taking new and promising laboratory insights and developing them into biology-based treatment approaches for patients with AML, CML, and MDS. His work has evolved from collaborations with many laboratory-based physician-scientists and he has translated numerous novel therapies into the clinic, including differentiation-based strategies, small molecule inhibitors of signal transduction pathways, agents that alter cell cycle kinetics and DNA-damage repair, and immunomodulatory approaches. Many of these trials share the common theme of studying the impact of the treatment on the cancer stem cells in hopes of limiting their role in treatment failure. Dr. Smith’s work integrates correlative studies to assess biologic activity of the experimental therapies.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-15-052-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Jonathan Webster and Dr. B. Douglas Smith have disclosed no relevant financial relationships.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Webster and Dr. Smith have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Webster and Dr. Smith have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at info@managingcml.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from ARIAD Pharmaceuticals, Inc., Novartis, and Teva Pharmaceuticals.

©2015 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.